Paulo Costa Net Worth

The estimated Net Worth of Paulo F Costa is at least $411 Thousand dollars as of 3 March 2016. Mr. Costa owns over 10,000 units of CorMedix Inc stock worth over $410,696 and over the last 11 years he sold CRMD stock worth over $0. In addition, he makes $0 as Director at CorMedix Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Costa CRMD stock SEC Form 4 insiders trading

Paulo has made over 2 trades of the CorMedix Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of CRMD stock worth $172,000 on 3 March 2016.

The largest trade he's ever made was buying 10,000 units of CorMedix Inc stock on 3 March 2016 worth over $172,000. On average, Paulo trades about 1,176 units every 0 days since 2013. As of 3 March 2016 he still owns at least 59,435 units of CorMedix Inc stock.

You can see the complete history of Mr. Costa stock trades at the bottom of the page.

Paulo Costa biography

Paulo F. Costa serves as Director of the Company. He served as President and Chief Executive Officer of Novartis U.S. Corporation, from October 2005 to August 2008. Prior to his work at Novartis U.S. Corporation, Mr. Costa was President and Chief Executive Officer of Novartis Pharmaceuticals, U.S. from July 1999 to September 2005. Prior to joining Novartis, Mr. Costa spent 30 years at Johnson & Johnson, including as President of Janssen Pharmaceutica, Inc. From August 2009 to August 2012, Mr. Costa served as Chairman of the Board of Amylin Pharmaceuticals Inc, a commercial stage biopharma company, until its sale to Bristol-Myers Squibb and AstraZeneca in a $7 billion transaction in 2012. Mr. Costa currently serves as Chairman of the Board of MacroGenics, Inc., a public late stage biopharma company focused on oncology, and as a director of two privately held life science companies.

How old is Paulo Costa?

Paulo Costa is 70, he's been the Director of CorMedix Inc since 2020. There are 4 older and 9 younger executives at CorMedix Inc. The oldest executive at CorMedix Inc is John L. Armstrong Jr., 76, who is the Exec. VP for Technical Operations.

What's Paulo Costa's mailing address?

Paulo's mailing address filed with the SEC is C/O CORMEDIX INC., 300 CONNELL DRIVE, BERKELEY HEIGHTS, NJ, 07922.

Insiders trading at CorMedix Inc

Over the last 14 years, insiders at CorMedix Inc have traded over $693,980 worth of CorMedix Inc stock and bought 2,651,866 units worth $3,532,566 . The most active insiders traders include Mehmood Khan, Gary A. Gelbfish, and Brian Lenz. On average, CorMedix Inc executives and independent directors trade stock every 30 days with the average trade being worth of $199,105. The most recent stock trade was executed by Joseph Todisco on 13 March 2024, trading 13,561 units of CRMD stock currently worth $50,718.

What does CorMedix Inc do?

cormedix inc. is a company based out of 745 route 202-206, suite 303, bridgewater, nj, united states.

Complete history of Mr. Costa stock trades at Macrogenics Inc and CorMedix Inc

CorMedix Inc executives and stock owners

CorMedix Inc executives and other stock owners filed with the SEC include:

• Khoso Baluch,
  Chief Executive Officer, Interim Principal Accounting Officer, Director
• Phoebe Mounts,
  Executive Vice President, General Counsel, Head of Regulatory, Compliance and Legal
• Elizabeth Masson,
  Executive Vice President - Head of Clinical Operations
• Khoso Baluch,
  CEO & Director
• Dr. Phoebe Mounts Esq.,
  Exec. VP, Gen. Counsel, Sec. and Head of Regulatory, Compliance & Legal
• John Armstrong,
  Executive Vice President - Technical Operations
• Elizabeth Masson-Hurlburt,
  Exec. VP & Head of Clinical Operations
• John L. Armstrong Jr.,
  Exec. VP for Technical Operations
• Alan Dunton,
  Independent Director
• Myron Kaplan,
  Independent Chairman of the Board
• Steven Lefkowitz,
  Independent Director
• Janet Dillione,
  Independent Director
• Gregory Duncan,
  Director
• Paulo Costa,
  Director
• Matthew David,
  Chief Financial Officer, Executive Vice President
• Thomas Nusbickel,
  Exec. VP & Chief Commercial Officer
• Dr. Paul Chew M.D.,
  Acting Chief Medical Officer
• Dr. Paul Chew,
  Acting Chief Medical Officer
• Dr. Matthew T. David M.D.,
  Exec. VP & CFO
• Judith R Abrams,
  Chief Medical Officer
• Robert W. Cook,
  Chief Financial Officer
• Taunia Markvicka,
  Director
• Antony Pfaffle,
  Director
• Randy Milby,
  Chief Operating Officer
• Cora M Tellez,
  Director
• Mehmood Khan,
  
• Michael W George,
  Director
• Gary A. Gelbfish,
  Director
• James Lefkowitz,
  Director
• Bami Bastani,
  Director
• Timothy M Hofer,
  Secretary
• Mark T. Houser,
  Chief Medical Officer
• John C. Houghton,
  President and CEO
• Mark A. Klausner,
  Chief Medical Officer
• Russell H Ellison,
  Director
• Robert A Stewart,
  
• Matthew Duffy,
  Director
• Harry O'grady,
  Chief Financial Officer
• Richard Cohen,
  Director
• Development Inc Pharmabio,
  10% owner
• Brian Lenz,
  Chief Financial Officer
• Thomas Nusbickel,
  EVP, Chief Commercial Officer
• Joseph Todisco,
  Chief Executive Officer
• Kaufman Beth Zelnick,
  Chief Legal Officer
• Erin Mistry,
  Chief Commercial Officer